Is chaos in US health policy creating new global opportunities? With major leadership and policy shake-ups the US healthcare ...

Technology has also improved immunisation operations with the use of online appointment scheduling that automates ...

The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...

Big Biotech Biogen is venturing into the city, paying $16 million in cash to partner up with an RNAi company to build next-gen central nervous system drugs. | Big Biotech Biogen is venturing into ...

" Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures ...

Moreover, global biotech Biogen has built ties with Massachusetts-based RNA therapeutics company Stoke Therapeutics. The latter’s antisense oligonucleotide zorevunersen is presently in clinical trials ...

Learn more about whether Biogen Inc. or Insmed Incorporated is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Biogen and Stoke Therapeutics have reached an agreement to develop and commercialize zorevunersen, a potential first-in-class disease-modifying therapy for Dravet syndrome, in all regions outside of ...

Biogen gains rights to Stoke’s Dravet syndrome candidate in deal worth $550m The rare genetic epilepsy affects up to 38,000 people in the US, UK, EU and Japan Biogen and Stoke Therapeutics have ...

CAMBRIDGE, Mass. - Biogen Inc. (NASDAQ: BIIB), a prominent biotechnology company with a $20.1 billion market cap currently trading near its 52-week low, and Stoke Therapeutics, Inc. (NASDAQ: STOK) ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico, and the US.